What was the market valuation of the US nausea medicine market in 2024?

The market valuation of the US nausea medicine market was $800.0 Million in 2024. Read More

What is the projected market valuation for the US nausea medicine market by 2035?

The projected market valuation for the US nausea medicine market is $1700.0 Million by 2035. Read More

What is the expected CAGR for the US nausea medicine market during the forecast period 2025 - 2035?

The expected CAGR for the US nausea medicine market during the forecast period 2025 - 2035 is 7.09%. Read More

Which companies are considered key players in the US nausea medicine market?

Key players in the US nausea medicine market include Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Bayer, Novartis, Sanofi, Merck & Co., Johnson & Johnson, and AstraZeneca. Read More

What are the main segments of the US nausea medicine market by type?

The main segments by type include Antagonists ($200.0 - $400.0 Million), Antihistamines ($250.0 - $500.0 Million), Cannabinoids ($150.0 - $300.0 Million), and Others ($200.0 - $500.0 Million). Read More

How is the US nausea medicine market segmented by mode of administration?

The market is segmented by mode of administration into Intravenous ($120.0 - $250.0 Million), Oral ($480.0 - $1000.0 Million), and Transdermal ($200.0 - $450.0 Million). Read More

What indications are covered in the US nausea medicine market?

Indications in the market include Oncology ($160.0 - $370.0 Million), Gastroesophageal Reflux Disease (GERD) ($240.0 - $510.0 Million), Motion Sickness and Seasickness ($160.0 - $370.0 Million), and Others ($240.0 - $450.0 Million). Read More

What distribution channels are utilized in the US nausea medicine market?

The distribution channels include Hospitals Pharmacy/Retail Pharmacy ($400.0 - $850.0 Million) and Online ($400.0 - $850.0 Million). Read More

What trends are expected in the US nausea medicine market by 2035?

By 2035, the US nausea medicine market is expected to experience substantial growth, potentially reaching a valuation of $1700.0 Million. Read More

How do the segment valuations reflect the overall market dynamics?

The segment valuations indicate a diverse market, with Oral administration and Antihistamines likely leading in revenue generation. Read More

US Nausea Medicine Market

US Nausea Medicine Market Research Report: By Type (Antagonists, Antihistamines, Cannabinoids, Others), By Mode of Administration (Intravenous, Oral, Transdermal), By Indication (Oncology, Gastroesophageal Reflux Disease (GERD), Motion Sickness, Seasickness, Others) and By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

7.09%

2024 Market Size

$ 800 Million

2035 Market Size

$ 1,700 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/12111-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Antagonists
  2. 4.1.2 Antihistamines
  3. 4.1.3 Cannabinoids
  4. 4.1.4 Others
2. 4.2 Industrial Automation & Equipment, BY Mode of Administration (USD Million)
  1. 4.2.1 Intravenous
  2. 4.2.2 Oral
  3. 4.2.3 Transdermal
3. 4.3 Industrial Automation & Equipment, BY Indication (USD Million)
  1. 4.3.1 Oncology
  2. 4.3.2 Gastroesophageal Reflux Disease (GERD)
  3. 4.3.3 Motion Sickness And Seasickness
  4. 4.3.4 Others
4. 4.4 Industrial Automation & Equipment, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospitals Pharmacy/ Retail Pharmacy
  2. 4.4.2 Online
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol-Myers Squibb (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GlaxoSmithKline (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bayer (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY MODE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY INDICATION
5. 6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY MODE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY MODE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY INDICATION, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY MODE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Nausea Medicine Market Segmentation

US Nausea Medicine Market By Type (USD Million, 2025-2035)

Antagonists
Antihistamines
Cannabinoids
Others

US Nausea Medicine Market By Mode of Administration (USD Million, 2025-2035)

Intravenous
Oral
Transdermal

US Nausea Medicine Market By Indication (USD Million, 2025-2035)

Oncology
Gastroesophageal Reflux Disease (GERD)
Motion Sickness And Seasickness
Others

US Nausea Medicine Market By Distribution Channel (USD Million, 2025-2035)

Hospitals Pharmacy/ Retail Pharmacy
Online

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”